Skip to main content
. 2024 May 13;10:227. doi: 10.1038/s41420-024-01984-7

Fig. 5. The effect of inhibitors on PANoptosis induced by co-treatment of IFN-γ and TNF-α.

Fig. 5

Immunoblot analysis of pro-(P53), activated (P30) GSDMD, pro-(P53) and activated (P34) GSDME, pro-(P45) and activated (P20) CASP1; pro-(P35) and cleaved (P19 and P17) CASP3, pro-(P55) and cleaved (P18) CASP8, phosphorylated MLKL (pMLKL), phosphorylated RIPK1 (pRIPK1), and pro-(P75) and cleaved (P30) RIPK1, phosphorylated RIPK3 (pRIPK3), RIPK3 in DLD1, HCT116 (a, b, df), 293 T or HT29 (c) after co-treatment with IFN-γ and TNF-α or supplement with Emricasan, GSK'872, Z-IETD-FMK, VX-765 or Nec-1 for 24 h. ATP, GAPDH, and Lamin B1 were used as membrane, cytosolic, and nuclear internal control respectively. Data are representative of at least three independent experiments.